Wennerberg Ann, Galli Silvia, Albrektsson Tomas
Department of Prosthodontics, Malmö University, Malmö, Sweden ; Department of Biomaterials, Gothenburg University, Gothenburg, Sweden.
Clin Cosmet Investig Dent. 2011 Sep 5;3:59-67. doi: 10.2147/CCIDEN.S15949. Print 2011.
This review summarizes the present documentation for the SLActive surface, a hydrophilic and nanostructured surface produced by Straumann Company in Switzerland, and covers the results from 15 in vitro, 17 in vivo, and 16 clinical studies. The SLActive surface is a development of the large grit-blasted and acid-etched SLA surface, and is further processed to a high degree of hydrophilicity. In general, the in vitro and in vivo studies of the SLActive surface demonstrate a stronger cell and bone tissue response than for the predecessor, the SLA surface, produced by the same company. However, in most studies, this difference disappears after 6-8 weeks. In the clinical studies, a stronger bone response was reported for the SLActive surface during the early healing phase when compared with the SLA surface. However, the later biological response was quite similar for the two surfaces and both demonstrated very good clinical results.
本综述总结了关于SLActive表面的现有文献资料,该表面是瑞士士卓曼公司生产的一种亲水性纳米结构表面,涵盖了15项体外研究、17项体内研究和16项临床研究的结果。SLActive表面是大颗粒喷砂和酸蚀SLA表面的改进型,经过进一步处理后具有高度亲水性。总体而言,SLActive表面的体外和体内研究表明,与同公司生产的前身SLA表面相比,其细胞和骨组织反应更强。然而,在大多数研究中,这种差异在6 - 8周后消失。在临床研究中,与SLA表面相比,SLActive表面在早期愈合阶段报告有更强的骨反应。然而,两种表面后期的生物学反应非常相似,且均显示出非常好的临床效果。